The Giants of US MedTech: 2026 Market Report

## Industry Highlights & Trends While multi-national conglomerates like Johnson & Johnson and Medtronic continue to capture the top spots by sheer volume—often utilizing aggressive acquisition strategies to fuel growth—the underlying market forces are shifting. We are seeing a distinct surge in valuations for companies focused on robotics, minimally invasive surgeries, and continuous patient monitoring. > **Market Insight:** Market Cap doesn't always align linearly with Revenue. Companies like Intuitive Surgical (makers of the Da Vinci robot) command premium market valuations relative to their revenue, reflecting immense investor confidence in the future of automated, soft-tissue surgical platforms. Furthermore, it is worth noting that massive scale does not necessarily require public equity. Medline Industries remains fiercely private despite pulling in over $25 Billion in revenue, dominating the essential day-to-day supply chain of global healthcare. ## The 2026 MedTech Market Table | Rank | Company Name | Status / Ticker | Est. Annual Revenue ($B) | Est. Market Cap ($B) | | :--- | :--- | :--- | :--- | :--- | | 1 | **Medtronic** | Public (MDT) | $33.5B | $110.0B | | 2 | **Johnson & Johnson MedTech** | Public (JNJ) | $31.9B | $390.0B | | 3 | **Abbott (Device & Diagnostics)** | Public (ABT) | $28.3B | $195.0B | | 4 | **Medline Industries** | Private | $25.5B | N/A | | 5 | **Stryker** | Public (SYK) | $22.6B | $135.0B | | 6 | **GE HealthCare** | Public (GEHC) | $19.7B | $42.0B | | 7 | **Boston Scientific** | Public (BSX) | $16.7B | $112.0B | | 8 | **Becton, Dickinson (BD)** | Public (BDX) | $19.3B | $70.0B | | 9 | **Danaher Corporation** | Public (DHR) | $23.9B | $195.0B | | 10 | **Baxter International** | Public (BAX) | $14.8B | $18.5B | | 11 | **Thermo Fisher Scientific** | Public (TMO) | $42.8B | $225.0B | | 12 | **Solventum** | Public (SOLV) | $8.2B | $11.0B | | 13 | **Intuitive Surgical** | Public (ISRG) | $7.1B | $140.0B | | 14 | **Zimmer Biomet** | Public (ZBH) | $7.4B | $25.0B | | 15 | **Edwards Lifesciences** | Public (EW) | $6.0B | $45.0B | | 16 | **Align Technology** | Public (ALGN) | $3.9B | $22.0B | | 17 | **Dexcom** | Public (DXCM) | $3.6B | $48.0B | | 18 | **ResMed** | Public (RMD) | $4.2B | $32.0B | | 19 | **Hologic** | Public (HOLX) | $4.0B | $18.0B | | 20 | **The Cooper Companies** | Public (COO) | $3.6B | $19.5B | | 21 | **Dentsply Sirona** | Public (XRAY) | $3.9B | $6.5B | | 22 | **Teleflex** | Public (TFX) | $3.0B | $10.0B | | 23 | **Insulet** | Public (PODD) | $1.7B | $14.0B | | 24 | **ICU Medical** | Public (ICUI) | $2.3B | $2.5B | | 25 | **Masimo** | Public (MASI) | $2.1B | $7.0B | | 26 | **Globus Medical** | Public (GMED) | $2.4B | $6.8B | | 27 | **Penumbra** | Public (PEN) | $1.1B | $8.0B | | 28 | **Integra LifeSciences** | Public (IART) | $1.6B | $2.2B | | 29 | **Enovis** | Public (ENOV) | $1.7B | $3.0B | | 30 | **CONMED** | Public (CNMD) | $1.2B | $2.1B | | 31 | **Merit Medical Systems** | Public (MMSI) | $1.3B | $4.5B | | 32 | **Inspire Medical Systems** | Public (INSP) | $0.6B | $6.0B | | 33 | **Haemonetics** | Public (HAE) | $1.3B | $4.0B | | 34 | **Tandem Diabetes Care** | Public (TNDM) | $0.8B | $2.0B | | 35 | **Glaukos** | Public (GKOS) | $0.3B | $5.0B | | 36 | **Novocure** | Public (NVCR) | $0.5B | $1.8B | | 37 | **iRhythm Technologies** | Public (IRTC) | $0.5B | $3.5B | | 38 | **Exact Sciences** | Public (EXAS) | $2.5B | $12.0B | | 39 | **Avanos Medical** | Public (AVNS) | $0.7B | $0.9B | | 40 | **AtriCure** | Public (ATRC) | $0.4B | $1.5B | | 41 | **Orthofix** | Public (OFIX) | $0.7B | $0.6B | | 42 | **TransMedics Group** | Public (TMDX) | $0.2B | $3.0B | | 43 | **PROCEPT BioRobotics** | Public (PRCT) | $0.1B | $2.5B | | 44 | **Varex Imaging** | Public (VREX) | $0.9B | $0.7B | | 45 | **Artivion** | Public (AORT) | $0.3B | $0.8B | | 46 | **Silk Road Medical** | Public (SILK) | $0.2B | $0.9B | | 47 | **Outset Medical** | Public (OM) | $0.1B | $0.2B | | 48 | **Alphatec** | Public (ATEC) | $0.5B | $1.8B | | 49 | **Nevro** | Public (NVRO) | $0.4B | $0.5B | | 50 | **Treace Medical Concepts** | Public (TMCI) | $0.2B | $0.4B | | 51 | **AngioDynamics** | Public (ANGO) | $0.3B | $0.3B | | 52 | **Paragon 28** | Public (FNA) | $0.2B | $0.8B | | 53 | **Lantheus** | Public (LNTH) | $1.3B | $4.5B | | 54 | **Neogen** | Public (NEOG) | $0.9B | $3.0B | | 55 | **AxoGen** | Public (AXGN) | $0.2B | $0.3B | | 56 | **Inari Medical** | Public (NARI) | $0.5B | $2.5B | | 57 | **LeMaitre Vascular** | Public (LMAT) | $0.2B | $1.5B | *\*Financial data represents carefully estimated and aggregated figures based on 2025/2026 fiscal filings and recent market valuations. Market caps are highly volatile and subject to change. Private company caps are denoted as N/A.*